Wayne Miles
Immunology and Microbiology · The Ohio State University
Publications
149
Citations
1,256
Est. group size
~30
Recurring co-author estimate
Active years
34
Publishing since 1993
Wayne Miles studies how cancer cells control gene expression after genes are transcribed into RNA, focusing on processes like RNA binding proteins (e.g., PUMILIO), microRNAs, and alternative RNA processing, and how these mechanisms affect tumor growth and the immune system's ability to detect and attack cancer, particularly in triple-negative breast cancer and colorectal tumors. His work connects molecular RNA regulation to practical questions about why tumors resist immune-based therapies like PD-1/PD-L1 blockade.
Publication output has grown substantially over the past decade, with a sharp increase starting in 2022-2023 and continued high activity through 2025-2026, though much of this includes supplementary datasets alongside primary research articles.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- DICER1 dysregulation triggers reprogramming of a specific miRNA subset, promotes mesenchymal cell fates and slows TNBC tumorigenic phenotypes
Non-coding RNA Research · 2026
- Coordinated post-transcriptional regulation facilitates PD-L1 protein production and tumor immune suppression
Cancer Letters · 2026
- Psoriasin Confers Therapeutic Vulnerability to cPLA2 Inhibition via NHERF2/GSK3β Signaling in Triple-Negative Breast Cancer
SSRN Electronic Journal · 2026
- Alpha-synuclein abundance and localization are regulated by the RNA-binding protein PUMILIO1
Cell Reports · 2025
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
- Integrated neoantigen and immune cell profiling of POLε-mutant colorectal tumors reveals distinct immune sub-types
Research Square · 2025
- Data from Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation
2023
- Supplementary Tables 1 and 2 and Supplementary Figures 1 through 6 from Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation
2023
- Supplementary Tables 1 and 2 and Supplementary Figures 1 through 6 from Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation
2023
- Supplementary Table 1 from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
2023
- Supplementary Figures and Legends from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
2023
- Supplementary Table 2 from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
2023
- Supplementary Table 6 from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
2023
- Supplementary Table 3 from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
2023
- Supplementary Table 5 from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
2023
- Figshare×18
- Cancer Research×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Research Square×5
- Nucleic Acids Research×2
- Jing J. Wang
Immunology and Microbiology · The Ohio State University
- Xinru Zheng
Immunology and Microbiology · The Ohio State University
- Xuanxuan Xing
Immunology and Microbiology · The Ohio State University
- Evan H. Zhang
Immunology and Microbiology · The Ohio State University
- Beiyuan Liang
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile